How to Help Your Patients Find Colchicine in Stock: A Provider's Guide

Your Patients Can't Find Colchicine — Here's How You Can Help

As a prescriber, you've likely heard from patients that their pharmacy is out of Colchicine. It's a conversation that's become more common in recent years, and one that directly impacts patient outcomes — whether it's a gout patient suffering through an untreated flare or an FMF patient missing their daily dose.

While the supply situation isn't dire enough to make the FDA's official shortage list, the reality on the ground is that many pharmacies experience periodic stock-outs. This guide gives you five practical steps to help your patients find Colchicine and keep their treatment on track.

Current Colchicine Availability

In 2026, Colchicine is available in four FDA-approved formulations:

• Generic Colchicine 0.6 mg tablets — most commonly prescribed; multiple manufacturers
• Mitigare 0.6 mg capsules (Hikma) — approved for gout prophylaxis
• Gloperba oral solution (Scilex) — 0.6 mg per 5 mL; useful for patients who can't swallow pills
• Lodoco 0.5 mg tablets (Agepha) — approved for atherosclerotic cardiovascular disease

Stock-outs tend to affect specific formulations or manufacturers rather than all products simultaneously. This means that flexibility in prescribing can often solve the problem.

Why Patients Can't Find Colchicine

Understanding the barriers helps you guide patients more effectively:

• Limited manufacturer base: Fewer companies produce Colchicine compared to other generics, making supply more vulnerable to disruptions
• Increasing demand: The Lodoco cardiovascular indication (approved 2023) has expanded the prescribing population significantly
• Pharmacy ordering patterns: Large chain pharmacies use centralized ordering algorithms that may not stock sufficient Colchicine if their local demand data lags behind actual need
• Cost avoidance: Some patients abandon their prescription at the pharmacy counter when they see the cash price ($150–$250 for 30 tablets) — they may not know about discount coupons that bring the price to $8–$15
• Insurance barriers: Brand formulations may require prior authorization, and some plans impose step therapy requirements

For the full patient perspective on these challenges, see Colchicine Shortage Update: What Patients Need to Know.

What Providers Can Do: 5 Steps

Step 1: Prescribe With Flexibility

Small changes to how you write the prescription can significantly improve fill rates:

• Allow generic substitution — always write "substitution permitted" or use the generic name
• Consider specifying multiple acceptable formulations in your notes (e.g., tablets or capsules)
• For chronic use, prescribe 90-day supplies when possible — this reduces the frequency of stock-out encounters and is often cheaper per unit
• Use e-prescribing to mail-order pharmacies for maintenance therapy patients

Step 2: Recommend Medfinder

Direct patients to Medfinder, a real-time pharmacy stock search tool. Patients can search by medication and location to find which pharmacies near them currently have Colchicine in stock.

Consider adding this to your after-visit instructions: "If your pharmacy is out of Colchicine, visit medfinder.com to search for pharmacies near you that have it in stock."

Step 3: Point Patients to Cost Savings

Many patients don't know they can dramatically reduce their Colchicine cost with free discount coupons. At the point of prescribing, mention:

• GoodRx and SingleCare coupons: Can bring the price from $231 retail down to $8–$15 for 30 generic tablets
• Takeda's Help at Hand program: Provides Colcrys at no cost to eligible uninsured patients (helpathandpap.com)
• NeedyMeds and RxAssist: Directory of patient assistance programs for Colchicine and other medications

For a comprehensive list, refer patients to How to Save Money on Colchicine in 2026.

Step 4: Have Alternative Regimens Ready

When Colchicine is genuinely unavailable, having a backup plan avoids treatment gaps:

For acute gout flares:

• Indomethacin 50 mg TID for 2–3 days, then taper
• Naproxen 750 mg initially, then 250 mg every 8 hours for 5–7 days
• Prednisone 30–40 mg daily for 5 days (ideal for patients with renal impairment or NSAID contraindications)

For gout flare prophylaxis during ULT initiation:

• Low-dose Naproxen 250 mg daily
• Low-dose Prednisone 5–7.5 mg daily

For FMF:

• No direct oral alternative — refer to rheumatology for biologic options (Anakinra, Canakinumab) if Colchicine is not obtainable

For recurrent pericarditis:

• NSAIDs (Ibuprofen 600 mg TID, Indomethacin 50 mg TID) ± aspirin
• Corticosteroid taper for refractory cases
• Rilonacept (Arcalyst) or Anakinra for patients failing first-line therapy

The patient-facing version of this information is available at Alternatives to Colchicine.

Step 5: Build a Local Pharmacy Network

Identify 2–3 independent pharmacies in your area that reliably stock Colchicine. Independent pharmacies often have access to multiple wholesalers and more flexibility in ordering. Building a relationship with these pharmacies can benefit all your patients on harder-to-find medications.

Consider maintaining a shared list within your practice of:

• Independent pharmacies that stock Colchicine consistently
• Mail-order pharmacies your patients have had success with
• Specialty pharmacies for complex cases (FMF, concurrent immunosuppressive therapy)

Workflow Tips for Your Practice

Integrating these steps into your workflow doesn't have to be complicated:

• EHR smart phrases: Create templates for after-visit summaries that include Medfinder links and discount coupon information
• Front desk handout: A simple one-page guide for patients on how to find medications in short supply
• Prior auth support: Have your team proactively submit prior authorizations for brand Colchicine when generic may be unavailable
• Patient portal messages: Send proactive messages to patients on Colchicine about refill strategies and alternative pharmacy options

Understanding Drug Interactions in the Expanding Patient Population

With Colchicine now prescribed for cardiovascular patients alongside statins, calcium channel blockers, and antiplatelet agents, drug interaction vigilance is paramount:

• Statins: Concurrent use increases myopathy and rhabdomyolysis risk — monitor for muscle symptoms
• Diltiazem and Verapamil: Moderate CYP3A4 inhibitors requiring Colchicine dose adjustment
• Clarithromycin: Contraindicated with Colchicine in patients with renal/hepatic impairment — fatal cases reported
• Cyclosporine: P-glycoprotein inhibitor; concomitant use with Colchicine is high-risk

For a comprehensive interaction reference: Colchicine Drug Interactions: What to Avoid.

Final Thoughts

Colchicine availability in 2026 is manageable but requires proactive effort from both providers and patients. By prescribing flexibly, connecting patients with stock-finding tools like Medfinder, addressing cost barriers, and having alternative regimens ready, you can minimize treatment disruptions and keep your patients on track.

For more provider resources, visit medfinder.com/providers.